Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation

Journal of the National Cancer Institute

Volumn 106, Issue 3, 2014, Pages

  Mukherjee, Sudipto ^a   Reddy, Chandana A ^a   Ciezki, Jay P ^a   Abdel Wahab, May ^a   Tiu, Ramon V ^a   Copelan, Edward ^b   Advani, Anjali A ^a   Saunthararajah, Yogen ^a   Paulic, Katarina ^a   Hobson, Sean ^a   Maciejewski, Jaroslaw P ^a   Bolwell, Brian J ^a   Kalaycio, Matt ^a   Dreicer, Robert ^a   Klein, Eric A ^c   Sekeres, Mikkael A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LEVINE CANCER INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SURGERY; COHORT ANALYSIS; COMPUTER ASSISTED RADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; VERY ELDERLY; ADENOCARCINOMA; BLOOD; FOLLOW UP; INCIDENCE; MIDDLE AGED; PROSTATE TUMOR; RADIATION DOSE; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84898732161     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt462     Document Type: Article

References (66)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Kleinerman RA, Liebermann JV, Li FP. Second cancer following cancer of the male genital system in Connecticut, 1935-82. Natl Cancer Inst Monogr. 1985;68:139-147.
3. Osterlind A, Rorth M, Prener A. Second cancer following cancer of the male genital system in Denmark, 1943-80. Natl Cancer Inst Monogr. 1985;68:341-347.
4. Teppo L, Pukkala E, Saxen E. Multiple cancer: an epidemiological exercise in Finland. J Natl Cancer Inst. 1985;75(2):207-217.
5. McCredie M, MacFarlane GJ, Stewart J, et al. Second primary cancers following cancers of the kidney and prostate in New South Wales (Australia), 1972-91. Cancer Causes Control. 1996;7(3):337-344.
6. Pawlish KS, Schottenfeld D, Severson R, et al. Risk of multiple primary cancers in prostate cancer patients in the Detroit metropolitan area: a retrospective cohort study. Prostate. 1997;33(2):75-86.
7. Pickles T, Phillips N. The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984-2000. Radiat Oncol. 2002;65(3):145-151.
8. Boorjian S, Cowan JE, Konety BR, et al. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavour. J Urol. 2007;177(3):883-887.
9. Neugut AI, Ahsan H, Robinson E, et al. Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer. 1997;79(8):1600-1604.
10. Moon K, Stukenborg GJ, Keim J, et al. Cancer incidence after localized therapy for prostate cancer. Cancer. 2006;107(5):991-998.
11. Brenner DJ, Curtis RE, Hall EJ, et al. Second malignancies in prostate cancer patients after radiotherapy compared with surgery. Cancer. 2000;88(2):398-406.
12. Baxter NN, Tepper JE, Durham SB, et al. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology. 2005;128(4):819-824.
13. Abdel-Wahab M, Reis IM, Wu J, et al. Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data. Urology. 2009;74(4):866-871.
14. McMaster ML, Feuer EJ, Tucker MA. New malignancies following cancer of the male genital tract. In: Curtis RE, ed. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute, NIH Publ. No. 05-5302. Bethesda, MD; 2006:257-284.
15. Ojha RP, Fischbach LA, Zhou Y, et al. Acute myeloid leukemia incidence following radiation therapy for localized or locally advanced prostate adenocarcinoma. Cancer Epidemiol. 2010;34(3):274-278.
16. Howlader M, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. National Cancer Institute, Section 30.Bethesda, MD. http:// seer.cancer.gov/csr/1975-2008/ based on November 2010 SEER data submission, posted to the SEER web site, 2011. Accessed January 23, 2014.
17. Sekeres MA, Schoonen WM, Kantarijan H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008;100(21):1542-1551.
18. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21(5):897-906.
19. Lavey RS, Eby NL, Prosnitz LR. Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer. 1990;66(1):80-88.
20. Kaplan HG, Malmgren JA, Atwood MK. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005. BMC Cancer. 2011;11:260.
21. Shuryak I, Sachs RK, Hlatky L, et al. Radiation-induced leukemia at doses relevant to radiation therapy: modeling mechanisms and estimating risks. J Natl Cancer Inst. 2006;98(24):1794-1806.
22. Cristy M. Active bone marrow distribution as a function of age in humans. Phys Med Biol. 1981;26(3):389-400.
23. Massberg S, von Andrian UH. Novel trafficking routes for hematopoietic stem and progenitor cells. Ann N Y Acad Sci. 2009;1176(1):87-93.
24. de Gonzalez AB, Curtis RE, Kry SF, et al. The proportion of second cancers attributable to radiotherapy treatment in adults: a prospective cohort study in the US SEER cancer registries. Lancet Oncol. 2011;12(4):353-360.
25. Fleming ID, Cooper JS, Henson DE, et al. AJCC on Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997.
26. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974.
27. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
28. Mohan DS, Kupelian PA, Willoughby TR. Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland. Int J Radiat Onc Biol Phys. 2000;46(3):575-580.
29. Kupelian PA, Reddy CA, Klein EA, et al. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Onc Biol Phys. 2001;51(4):988-993.
30. Wilkinson DA, Lee EJ, Ciezki JP, et al. Dosimetric comparison of preplanned and or-planned prostate seed brachytherapy. Int J Radiat Onc Biol Phys. 2000;48(4):1241-1244.
31. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-199.
32. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
33. American Society of Hematology. Changes impacting hematology ICD-9 codes become effective October 1, 2009. http://www.hematology.org/ News/2009/4282.aspx. Accessed January 23, 2014.
34. Valent P, Horny H-P, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31(6):727-736.
35. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1998;89(6):2079-2088. Erratum in: Blood. 1998;91(3):1100.
36. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
37. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
38. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45-52.
39. De Roos AJ, Deeg HJ, Davis S. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers. Cancer Causes Control. 2007;18(10):1199-1208.
40. Wallner LP, Wang R, Jacobsen SJ, et al. Androgen deprivation therapy for treatment of localized prostate cancer and risk of secondary primary malignancies. Cancer Epidemiol Biomarkers Prev. 2013;22(2):313-316.
41. Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol. 2003;21(7):1195-1204.
42. Fisher B, Rockette H, Fisher ER, et al. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience. J Clin Oncol. 1985;3(12):1640-1658.
43. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Ann Intern Med. 1985;103(2):195-200.
44. MacDougall BK, Weinerman BH, Kemel S. Second malignancies in non- Hodgkin's lymphoma. Cancer. 1981;48(6):1299-1301.
45. Gomez GA, Agganval KK, Han T. Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non- Hodgkin's lymphoma: correlation with intensity of treatment. Cancer. 1982;50(11):2285- 2288.
46. Blayney DW, Longo DL, Young RC, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med. 1987;316(12):710-714.
47. Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin's disease. New Engl J Med. 1990;322(1):7-13.
48. Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988;318(2):76-81.
49. Valagussa P, Santoro A, Fossati-Bellani F, et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol. 1986;4(6):830-837.
50. Papa G, Mauro FR, Anselmo AP, et al. Acute leukaemia in patients treated for Hodgkin's disease. Br J Haematol. 1984;58(1):43-52.
51. Tester WJ, Kinsella TJ, Waller B et al. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. J Clin Oncol. 1984;2(7):762-769.
52. Van Rijswijk REN, Verbeck J, Hannen C, et al. Major complications and causes of death in patients treated for Hodgkin's disease. J Clin Oncol. 1987;5(10):1624-1633.
53. Brusamolino E, Lazzarino M, Salvaneschi L et al. Risk of leukemia in patients treated for Hodgkin's disease. Eur J Cancer Clin Oncol. 1982;18(3):237-242.
54. Glicksman AS, Pajak TF, Gottlieb A, et al. Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study. Cancer Treat Rep. 1982;66(4):1035-1044.
55. Pedersen-Bjergaard J, Larsen SO. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med. 1982;307:965-971.
56. Pedersen-Bjeergaard J, Larsen So, Struck J, et al. Risk of therapy related leukaemia and preleukaemia after Hodglan's disease. Lancet. 1987;2(8550):83-88.
57. Bartolucci AA, Liu C, Durant JR, et al. Acute myelogenous leukemia as a second malignant neoplasm following the successful treatment of advanced Hodgkin's disease. Cancer. 1983;52(12):2209-2213.
58. Boivin JF, Hutchison GB, Lyden M, et al. Second primary cancers following treatment of Hodgkin's disease. J Nat Cancer Inst. 1984;72(2):233-241.
59. Mauch PM, Canellos GP, Rosenthal DS, et al. Reduction of fatal complications from combined modality therapy in Hodgkin's disease. J Clin Oncol. 1985;3(4):501-505.
60. Henry-Amar M. Second cancers after radiotherapy and chemotherapy for early stages of Hodgkin's disease. J Natl Cancer Inst. 1983;71(5):911-916.
61. Koletsky AJ, Bertino JR, Farber LR, et al. Second neoplasms in patients with Hodgkin's disease following combined modality therapy: the Yale experience. J Clin Oncol. 1986;4(3):311-317.
62. Travis LB, Weeks J, Curtis RE, et al. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. J Clin Oncol. 1996;14(2):565-571.
63. Mendenhall NP, Noyes WD, Million RR. Total body irradiation for stage II-IV non-Hodgkin's lymphoma: ten-year follow-up. J Clin Oncol. 1989;7(1):67-74.
64. Valent P, Horny HP. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest. 2009;39(7):548-553.
65. Iwanaga M, Hsu WL, Soda M, et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol. 2011;29(4):428-434.
66. Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010:28(17):2847-2852.